Thomas J. Moore, of the Institute for Safe Medication Practices, recently wrote a “Perspective” piece about new Pradaxa-versus-warfarin study, which is described below. Medical researchers reviewed population-wide electronic medical records from the Clinical Data Analysis and Reporting System of the Hong Kong Hospital Authority to identify the … [Read more...]
Earlier Pradaxa Settlements Do Not Stop Filing Of New Pradaxa Lawsuits
As can be seen from the following set of drug safety alerts, Pradaxa has caused significant concern among doctors and patients since soon after it first became available for use in the US. In early December 2011 the FDA announced it would evaluate reports of bleeding in patients taking Pradaxa that have been submitted to the agency’s Adverse … [Read more...]
Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
On October 13, 2016 attorneys for Bristol-Myers Squibb Company and Pfizer Inc. filed with the United States Judicial Panel on Multidistrict Litigation (JPML) this court document, “BRISTOL-MYERS SQUIBB COMPANY AND PFIZER INC.’S MOTION FOR TRANSFER OF RELATED ELIQUIS (APIXABAN) PRODUCTS LIABILITY ACTIONS FOR COORDINATED PRETRIAL PROCEEDINGS PURSUANT … [Read more...]
Warfarin vs. Eliquis, Pradaxa, Xarelto, and Savaysa: Which is Better?
There in an ongoing debate amongst medical professionals concerning the effectiveness and safety of warfarin in comparison to the non–vitamin K antagonist oral anticoagulants (NOACs)--such as Eliquis, Xarelto, Savaysa, and Pradaxa--for patients with atrial fibrillation. According to the Healio Cardiology today article, "Merits of warfarin, newer … [Read more...]
Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
In this article published online by Pharmacy Times in August 2016, “Is Apixaban Safe and Effective for Patients on Hemodialysis?”, Brandon Dyson, PharmD, BCPS, who is a clinical pharmacist at an academic medical center, puts some scrutiny on Eliquis, an increasingly popular blood-thinner drug: [Eliquis (apixaban)] is the only [novel oral … [Read more...]
What’s in a Name? Debate on What to Call Novel Oral Anticoagulants
Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis. The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]